Business · 02/04/2026Updated: 10/16/2026 · 1 min read
FDA Awards Priority Review Voucher to Rocket Pharmaceuticals for Rare Pediatric Disease Product KRESLADI
Summary
The FDA has awarded a priority review voucher to Rocket Pharmaceuticals, Inc. for its rare pediatric disease product KRESLADI, following its approval on March 26, 2026.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →